The Medicines Company announced the approval of cangrelor (Kengreal) by the U.S. Food and Drug Administration (FDA) as an adjunctive therapy to percutaneous coronary intervention (PCI). The novel, intravenous antiplatelet agent is indicated for reducing periprocedural thrombotic events in patients who have not been treated with a P2Y12 inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor (GPI).

The American Society of Echocardiography (ASE) and Ke Labs jointly announced in May an agreement to co-develop and co-market a new cardiac ultrasound software application. The application is designed to ensure quality and consistency of cardiac ultrasound image review — both quantitatively and qualitatively — and inform and educate users on interesting cases, new techniques and other changes. This medical imaging quality management software tool is generally referred to as the “Echocardiography Test and Teach Application,” and it has been designed through the expert guidance of Harvey Feigenbaum, M.D., FASE with the Krannert Institute of Cardiology at Indiana University Health and founder of the ASE.

Epsilon Imaging Inc. announced that several studies were presented at the American Society of Echocardiography (ASE) 2015 conference, June 13-16, on its EchoInsight automated measurement suite for improved analysis and interpretation in echo.

Agfa HealthCare announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for diagnostic viewing with the XERO Viewer. This Full Fidelity View functionality of the viewer uses lossless compression to provide diagnostic quality when images are displayed, by retrieving original-quality renditions of stored digital X-ray (DX), computed tomography (CT), magnetic resonance imaging (MRI), computed radiography (CR) and ultrasound (US) images.

Pie Medical Imaging announced its new release of CAAS MRV, for analysis of the heart to support diagnosis of cardiovascular conditions. This new version contains intuitive and guided analysis workflows, optimized to clinical practice. The workflows guide users through the required steps for functional left and right ventricle, viability and first pass perfusion analysis. The new viability workflow includes, besides analysis of delayed enhanced MR (magnetic resonance) images, also analysis of edema on T2-weighted MR images. The combination of segmented infarcts and edema areas can identify the salvageable areas.

ClearFlow Inc. announced that the U.S. Food & Drug Administration (FDA) has granted expanded Indications for Use of the company's patented PleuraFlow Active Clearance Technology system. The PleuraFlow system is a patented medical device that prevents chest drains from occluding with clot, which can lead to retained blood around the heart and lungs.

Edwards Lifesciences Corp. announced U.S. Food and Drug Administration (FDA) approval of the Edwards Sapien 3 valve with the Commander Delivery System for the treatment of high-risk patients suffering from severe, symptomatic aortic stenosis.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now